Current Report · 8-K
Gossamer Bio, Inc.
GOSSNASDAQEQUITYCurrent
Current Report
Company context
Gossamer Bio is a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its goal is to be an industry leader in, and to enhance the lives of patients living with, pulmonary hypertension.